UK IPO rejects revocation action by Biogene against Enigma's patents

Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced that the UK Intellectual Property Office (IPO) has rejected a revocation action brought by Biogene against three patents licensed exclusively to Enigma by the Defence Science and Technology Laboratory (Dstl), part of the UK Ministry of Defence. The patents cover electrically conducting polymer (ECP) thermal cycling technology which is used in Enigma's fully automated real-time PCR system, the Enigma ML, to enable rapid molecular testing at the point of care.

On 9th August 2010 the IPO issued summary judgement against Biogene and awarded costs to Dstl. The absence of any subsequent appeal to the High Court means that these patents are now free from any challenge.

The ECP patents are part of Enigma's extensive intellectual property portfolio, covering molecular diagnostics and sample preparation technologies, which comprises of over 350 patent filings including 220 granted cases.